Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Search
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Early Access Treatments & Compassionate Use Programs
Explore how we facilitate patient access to investigational and/or unlicensed medicines through our individual requests and Compassionate Use programs
The unseen lameness problem in horses
Learn more about the signs, causes and preventive measures of lameness in horses.
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Chronic kidney disease in cats
Detect and manage chronic kidney disease and high blood pressure in cats
Benefits of Pradaxa®
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Helping smallholder farmers after Covid-19
In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Powered By Our People – A Global IT Community
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
More Green
More Green
Patient voices Augustos story
Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Eves story
Eve’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Ulrichs story
Ulrich’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Newsbits
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.